natalizumab

ApprovedWithdrawn

1 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Crohn's Disease

Conditions

Crohn's Disease

Trial Timeline

Dec 1, 2008 → —

NCT ID

NCT00801125

About natalizumab

natalizumab is a approved stage product being developed by Biogen for Crohn's Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00801125. Target conditions include Crohn's Disease.

What happened to similar drugs?

8 of 20 similar drugs in Crohn's Disease were approved

Approved (8) Terminated (3) Active (12)

✅adalimumabAbbVieApproved

✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved

✅Infliximab + Prednisolone + AzathioprinePfizerApproved

✅Celebrex + placeboPfizerApproved

✅Cimzia + MesalamineUCBApproved

✅Certolizumab PegolUCBApproved

✅certolizumab pegol + certolizumab pegol + certolizumab pegol + certolizumab pegolUCBApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05925049	Pre-clinical	Active	Jun 30, 2023	Mar 31, 2026	Multiple Sclerosis
NCT05701423	Pre-clinical	Terminated	Feb 8, 2023	Jul 31, 2024	Multiple Sclerosis
NCT05532163	Approved	Terminated	Jan 23, 2023	Oct 9, 2023	Multiple Sclerosis, Relapsing-Remitting
NCT05265728	Phase 3	Terminated	Apr 26, 2022	May 27, 2024	Multiple Sclerosis, Relapsing-Remitting
NCT05304520	Pre-clinical	Completed	Oct 12, 2021	Apr 30, 2024	Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT05236777	Pre-clinical	Completed	Jan 1, 2019	Apr 30, 2025	Multiple Sclerosis
NCT03283371	Phase 2	Completed	Mar 20, 2018	Nov 18, 2020	Epilepsy, Focal Seizures, Partial Seizures
NCT02677077	Pre-clinical	Completed	Dec 31, 2015	Aug 18, 2016	Relapsing-Remitting Multiple Sclerosis
NCT02386566	Pre-clinical	Completed	Mar 20, 2015	Jan 28, 2018	Multiple Sclerosis
NCT02142192	Phase 2	Terminated	Dec 1, 2014	Jun 4, 2015	Relapsing Multiple Sclerosis
NCT02241785	Approved	Terminated	Sep 30, 2014	May 2, 2016	Relapsing Multiple Sclerosis
NCT02137109	Pre-clinical	Completed	Mar 1, 2014	Oct 1, 2015	Multiple Sclerosis
NCT04832399	Pre-clinical	Completed	Nov 12, 2013	Oct 2, 2023	Relapsing Remitting Multiple Sclerosis
NCT01884935	Phase 1	Completed	Jul 1, 2013	Sep 1, 2014	Relapsing-Remitting Multiple Sclerosis
NCT01485003	Pre-clinical	Completed	Feb 7, 2012	Nov 26, 2018	Relapsing-Remitting Multiple Sclerosis
NCT01943526	Pre-clinical	Completed	Nov 30, 2011	Dec 31, 2017	Relapsing-Remitting Multiple Sclerosis
NCT01416155	Phase 2	Completed	Oct 1, 2010	Dec 1, 2014	Relapsing-Remitting Multiple Sclerosis
NCT01077466	Phase 2	Completed	Mar 1, 2010	Jan 1, 2012	Primary Progressive Multiple Sclerosis
NCT01070836	Pre-clinical	Completed	Mar 1, 2010	Nov 1, 2015	Relapsing Multiple Sclerosis
NCT00801125	Approved	Withdrawn	Dec 1, 2008	—	Crohn's Disease

Competing Products

20 competing products in Crohn's Disease

See all competitors

Product	Company	Stage	Hype Score
CT-P13 + Remicade	Celltrion	Phase 3	40
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13	Celltrion	Phase 1	29
CT-P13 SC (Infliximab)	Celltrion	Phase 3	40
CP-461	Astellas Pharma	Phase 2	35
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kg	Eisai	Phase 1/2	32
E6011 + Placebo	Eisai	Phase 2	35
E6011 + Placebo	Eisai	Phase 1	21
adalimumab + adalimumab + placebo	Eisai	Phase 2/3	38
adalimumab	Eisai	Phase 2/3	38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + Placebo	Eli Lilly	Phase 3	40
Mirikizumab	Eli Lilly	Phase 3	47
Mirikizumab + Mirikizumab + Tirzepatide + Placebo	Eli Lilly	Phase 3	47
Mirikizumab + Placebo	Eli Lilly	Phase 2	35
Mirikizumab	Eli Lilly	Phase 3	44
Matching Placebo for Upadacitinib + Upadacitinib	AbbVie	Phase 3	40
Adalimumab + Placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo for Upadacitinib	AbbVie	Phase 3	40
Placebo + ABT-494	AbbVie	Phase 2	35
ABT-494	AbbVie	Phase 2	35
Risankizumab + Comparator	AbbVie	Pre-clinical	33